IL28B gene polymorphisms and Th1/Th2 cytokine levels might be associated with HTLV-associated arthropathy

Cytokine

Volumn 77, Issue , 2016, Pages 79-87

  de Sá, Keyla Santos Guedes ^a   Santana, Bárbara Brasil ^a   de Souza Ferreira, Tuane Carolina ^a   Sousa, Rita Catarina Medeiros ^a   Caldas, Cezar Augusto Muniz ^a   Azevedo, Vânia Nakauth ^a   Feitosa, Rosimar Neris Martins ^a   Machado, Luiz Fernando Almeida ^a   de Oliveira Guimarães Ishak, Marluísa ^a   Ishak, Ricardo ^a   Vallinoto, Antonio Carlos Rosário ^a  

^a FEDERAL UNIVERSITY OF PARÁ   (Brazil)

Author keywords

HTLV associated arthropathy; IL 28B; Rs12979860; Rs8099917; Rs8103142

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 28B; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOTOXIN; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTHROPATHY; ARTICLE; ASYMPTOMATIC DISEASE; CD4 LYMPHOCYTE COUNT; CD8+ T CELL COUNT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS INFECTION; HUMAN T LYMPHOTROPIC VIRUS ASSOCIATED ARTHROPATHY; IL28B GENE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SINGLE NUCLEOTIDE POLYMORPHISM; TH1 TH2 BALANCE; VIRUS LOAD; ALLELE; CD4+ T LYMPHOCYTE; DELTARETROVIRUS; DELTARETROVIRUS INFECTION; GENETICS; HOST PATHOGEN INTERACTION; INFECTIOUS ARTHRITIS; METABOLISM; PHYSIOLOGY; TH1 CELL; TH2 CELL; VIROLOGY;

ALLELES; ARTHRITIS, INFECTIOUS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DELTARETROVIRUS; DELTARETROVIRUS INFECTIONS; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-6; INTERLEUKINS; LYMPHOCYTE COUNT; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; TH1 CELLS; TH2 CELLS; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD;

EID: 84946423327     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.11.004     Document Type: Article

References (68)

1. Van Regenmortel MHV, Fauquet CM, Bishop DHL, Carstens EB, Estes MK, Lemon SM, et al. Virus Taxonomy. 9th Report of the International Committee on Taxonomy of Viruses. San Diego; 2011.
2. Rosenblatt J.D., Golde D.W., Wachsman W., Giorgi J.V., Jacobs A., Schmidt G.M., et al. A second isolate of HTLV-II associated with atypical hairy-cell leukemia. New Engl. J. Med. 1986, 315:372-377.
3. Poiesz B.J., Ruscetti F.W., Gazdar A.F., Bunn P.A., Minna J.D., Gallo R.C. Detection and isolation of Type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-Cell Lymphoma. Proc. Natl. Acad. Sci. USA 1980, 77:415-7419.
4. Yoshida M., Miyoshi I., Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc. Natl. Acad. Sci. USA 1982, 79:2031-2035.
5. Hall W.W., Ishak R., Zhu S.W., Novoa P., Eiraku N., Takahashi H., et al. Human T lymphotropic virus type II (HTLV-II): epidemiology, molecular properties, and clinical features of infection. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1996, 13:S204-S214.
6. Proietti F.A., Carneiro-Proietti A.B.F., Catalan-Soares B.C., Murphy E.L. Global epidemiology of HTLV-I infection and associated diseases. Oncogene 2005, 24:6058-6068.
7. Uchiyama T., Yodoi J., Sagawa K., Takatsuki K., Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 1977, 50:481-492.
8. Ribas J.G.R., Melo G.C.N. Human T-cell lymphotropic virus type 1(HTLV-1)-associated myelopathy. Rev. Soc. Bras. Med. Trop. 2002, 35:377-384.
9. Sato K., Maruyama I., Maruyama Y., Kitajima I., Nakajima Y., Higaki M., et al. Arthritis in patients infected with human T lymphotropic virus type I. Clinical and immunopathologic features. Arthritis Rheum. 1991, 34:714-721.
10. Hida A., Imaizumi M., Sera N., Akahoshi M., Soda M., Maeda R., et al. Association of human T lymphotropic virus type I with Sjogren syndrome. Ann. Rheum. Dis. 2010, 69:2056-2057.
11. Shirdel A., Hashemzadeh K., Sahebari M., Rafatpanah H., Hatef M., Rezaieyazdi Z., et al. Is there any association between human lymphotropic virus Type I (HTLV-I) infection and systemic lupus erythematosus? An original research and literature review. Iran J. Basic Med. Sci. 2013, 16:252-257.
12. Cruz B.A., Catalan-soares B., Proietti F. Rheumatic manifestations associated with the human T-cell lymphotropic virus Type I (HTLV-I). Rev. Bras. Reum. 2005, 45:71-77.
13. Yin W., Hasunuma T., Kobata T., Sumida T., Nishioka K. Synovial hyperplasia in HTLV-I associated arthropathy is induced by tumor necrosis factor-alpha produced by HTLV-I infected CD68+ cells. J. Rheumatol. 2000, 27:874-881.
14. Aono H., Fujisawa K., Hasunuma T., Marriott S.J., Nishioka K. Extracellular human T cell leukemia virus type 1 TAX protein stimulates the proliferation of human synovial cells. Arthritis Rheum. 1998, 41:1995-2003.
15. Richardson J.H., Edwards A.J., Cruickshank J.K., Rudge P., Dalgleish A.G. In vivo cellular tropism of human T-cell leukemia virus type 1. J. Virol. 1990, 64:5682-5687.
16. + T cells in cerebrospinal fluid from patients with HAM/TSP. Ann. Neurol. 2001, 50:807-812.
17. Jones K.S., Petrow-Sadowski C., Huang Y.K., Bertolette D.C., Ruscetti F.W. Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4(+) T cells. Nat. Med. 2008, 14:429-436.
18. Méndez E., Kawanishi T., Clemens K., Siomi H., Soldan S.S., Calabresi P., et al. Astrocyte-specific expression of human T-cell lymphotropic virus type 1 (HTLV-1) Tax : induction of tumor necrosis factor alpha and susceptibility to lysis by CD8 + HTLV-1-specific cytotoxic T Cells. J. Virol. 1997, 71:9143.
19. Bangham C.R. The immune response to HTLV-I. Curr. Opin. Immunol. 2000, 12:397-402.
20. Bangham C.R.M., Osame M. Cellular immune response to HTLV-1. Oncogene 2005, 24:6035-6046.
21. Ballard D.W., Böhnlein E., Lowenthal J.W., Wano Y., Franza B.R., Greene W.C. HTLV-I tax induces cellular proteins that activate the kappa B element in the IL-2 receptor alpha gene. Science 1988, 241:1652-1655.
22. Barmak K., Harhaj E.W., Wigdahl B. Mediators of central nervous system damage during the progression of human T-cell leukemia type I-associated myelopathy/tropical spastic paraparesis. J. Neurovirol. 2003, 9:522-529.
23. Meager A., Visvalingam K., Dilger P., Bryan D., Wadhwa M. Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine 2005, 31:109-118.
24. Robek M.D., Boyd B.S., Chisari F.V. Lambda interferon inhibits hepatitis B and C virus replication. J. Virol. 2005, 79:3851-3854.
25. Ank N., West H., Bartholdy C., Eriksson K., Thomsen A.R., Paludan S.R. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J. Virol. 2006, 80:4501-4509.
26. Morrow M.P., Yan J., Pankhong P., Shedlock D.J., Lewis M.G., Talbott K., et al. IL-28B/IFN-lambda 3 drives granzyme B loading and significantly increases CTL killing activity in macaques. Mol. Ther. 2010, 18:1714-1723.
27. Vallinoto A.C.R., Ishak M.O.G., Azevedo V.N., Vicente A.C.P., Otsuki K., Hall W.W., et al. Molecular epidemiology of human T-lymphotropic virus type II infection in Amerindian and urban populations of the Amazon region of Brazil. Hum. Biol. Int. Rec. Res. 2002, 74:633-644.
28. Tamegão-lopes B.P., Rezende P.R., Marade-Pereira L.M.C., Lemos J.A.R. HTLV-1 and HTLV-2 proviral load: a simple method using quantitative real-time PCR. Rev. Soc. Bras. Med. Trop. 2006, 39:548-552.
29. Barret JC, Fry B, Maller J, Daly MJ: Haploview: analysis and visualizations of LD and haplotype maps. 2005.
30. M. Ayres, J.R.M. Ayres, D.L. Ayres, A.S. Santos. BioEstat 5.0: Aplicações estatísticas nas áreas das ciências biológicas e medicas. 2008.
31. GraphPad Software I: Prism (data analysis software system), version 5. Software e Guia do Usuário. 2007.
32. Yakova M., Lézin A., Dantin F., Lagathu G., Olindo S., Jean-Baptiste G., et al. Increased proviral load in HTLV-1-infected patients with rheumatoid arthritis or connective tissue disease. Retrovirology 2005, 2:4.
33. Eguchi K., Nakamura T., Mine M., Ida H., Kawakami A., Migita K., et al. HTLV-I associated arthritis: characteristics of an HTLV-I virus infected T cell line from synovial fluid. Ann. Rheum. Dis. 1992, 51:673-677.
34. Nakajima T., Kitamura K., Yamashita N., Sakane T., Mizushima Y., Delespesse G., et al. Constitutive Expression and producion of tumor necrosis factor-B in T-cell lines infected with HTLV-1 and HTLV-2. Biochem. Biophys. Res. Commun. 1993, 191:371-377.
35. Straub R.H., Muller-Ladner U., Schölmerich J., Menninger H., Lang B. Decrease of interleukin 6 during the first 12 months is a prognostic marker for clinical outcome during 36 months treatment with disease-modifying anti-rheumatic drugs. Br. J. Rheumatol. 1997, 36:1298-1303.
36. Lee C.K., Lee E.Y., Chung S.M., Mun S.H., Yoo B., Moon H.B. Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. Arthritis Rheum. 2004, 50:3831-3843.
37. Cush J.J., Splawski J.B., Thomas R., McFarlin J.E., Schulze-Koops H., Davis L.S., et al. Elevated interleukin-10 levels in patients with rheumatoid arthritis. Arthritis Rheum. 1995, 38:96-104.
38. Mori N., Shirakawa F., Abe M., Kamo Y., Koyama Y., Murakami S., et al. Human T-cell leukemia virus type I tax transactivates the interleukin-6 gene in human rheumatoid synovial cells. J. Rheumatol. 1995, 22:2049-2054.
39. Le Goff B., Blanchard F., Berthelot J.-M., Heymann D., Maugars Y. Role for interleukin-6 in structural joint damage and systemic bone loss in rheumatoid arthritis. Joint Bone Spine. 2010, 77:201-205.
40. Mori N., Prager D. Interleukin-10 gene expression and adult T-cell leukemia. Leuk. Lymphoma 1998, 29:239-248.
41. Takatsuka N., Hasegawa A., Takamori A., Shimizu Y., Kato H., Ohashi T., et al. Induction of IL-10- and IFN-gamma-producing T-cell responses by autoreactive T-cells expressing human T-cell leukemia virus type I Tax. Int. Immunol. 2009, 21:1089-1100.
42. + T cells. J. Immunol. 1998, 160:3188-3193.
43. Santin A.D., Hermonat P.L., Ravaggi A., Bellone S., Pecorelli S., Roman J.J., et al. Interleukin-10 increases Th1 cytokine production and cytotoxic potential in human papillomavirus-specific CD8(+) cytotoxic T lymphocytes. J. Virol. 2000, 74:4729-4737.
44. Starling A.L.B., Martins-Filho O.A., Lambertucci J.R., Labanca L., de Souza Pereira S.R., Teixeira-Carvalho A., et al. Proviral load and the balance of serum cytokines in HTLV-1-asymptomatic infection and in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). Acta Trop. 2013, 125:75-81.
45. Goon P.K.C., Igakura T., Hanon E., Mosley A.J., Asquith B., Gould K.G., et al. High circulating frequencies of tumor necrosis factor alpha- and interleukin-2-secreting human T-lymphotropic virus Type 1 (HTLV-1)-specific CD4+ T cells in patients with HTLV-1-associated neurological disease. J. Virol. 2003, 77:9716-9722.
46. Coccia E.M., Severa M., Giacomini E., Monneron D., Remoli M.E., Julkunen I., et al. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur. J. Immunol. 2004, 34:796-805.
47. Gallagher G., Megjugorac N.J., Yu R.Y., Eskdale J., Gallagher G.E., Siegel R., et al. The lambda interferons: guardians of the immune-epithelial interface and the T-helper 2 response. J. Interferon Cytokine Res. 2010, 30:603-615.
48. Morrow M.P., Pankhong P., Laddy D.J., Schoenly K.A., Yan J., Cisper N., et al. Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood 2009, 113:5868-5877.
49. Kamihira S., Usui T., Ichikawa T., Uno N., Morinaga Y., Mori S., et al. Paradoxical expression of IL-28B mRNA in peripheral blood in human T-cell leukemia virus type-1 mono-infection and co-infection with hepatitis C virus. Virol. J. 2012, 9:40.
50. Treviño A., Lopez M., Vispo E., Aguilera A., Ramos J.M., Benito R., et al. Development of tropical spastic paraparesis in human T-lymphotropic virus type 1 carriers is influenced by interleukin 28B gene polymorphisms. Clin. Infect. Dis. 2012, 55:e1-e4.
51. Assone T., Souza F.V., Gaester K.O., Fonseca L.A.M., Luiz O.C., Malta F., et al. IL28B gene polymorphism SNP rs8099917 genotype GG is associated with HTLV-1-associatade myelophaty/Tropical spastic paraparesis (HAM/TSP) in HTLV-1 carriers. PLoS Negl Trop Dis. 2014, 8:e3199. 10.1371/journal.pntd.0003199.
52. Abe H., Hayes C.N., Ochi H., Maekawa T., Tsuge M., Miki D., et al. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J. Hepatol. 2011, 54:1094-1101.
53. Onomoto K., Morimoto S., Kawaguchi T., Toyoda H., Tanaka M., Kuroda M., et al. Dysregulation of IFN system can lead to poor response to pegylated interferon and ribavirin therapy in chronic hepatitis C. PLoS ONE 2011, 6:e19799.
54. Ahlenstiel G., Booth D.R., George J. IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. J. Gastroenterol. 2010, 45:903-910.
55. Ren S., Lu J., Du X., Huang Y., Ma L., Huo H., et al. Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma. Cancer Immunol. Immunother. 2012, 61:1433-1439.
56. Di Marco V., Bronte F., Calvaruso V., Capra M., Borsellino Z., Maggio A., et al. IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. Haematologica 2012, 97:679-686.
57. Hsu C.-S., Hsu S.-J., Chen H.-C., Tseng T.-C., Liu C.-H., Niu W.-F., et al. Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy. Proc. Natl. Acad. Sci. USA 2011, 108:3719-3724.
58. Miyamura T., Kanda T., Nakamura M., Jiang X., Wu S., Nakamoto S., et al. IL-28B polymorphisms and treatment response in hepatitis C virus patients with persistently normal alanine aminotransferase. World J. Hepatol. 2013, 5:635-641.
59. Iwakura Y., Saijo S., Kioka Y., Nakayama-Yamada J., Itagaki K., Tosu M., et al. Autoimmunity induction by human T cell leukemia virus type 1 in transgenic mice that develop chronic inflammatory arthropathy resembling rheumatoid arthritis in humans. J. Immunol. 1995, 155:1588-1598.
60. Bertolini D.R., Nedwin G.E., Bringman T.S., Smith D.D., Mundy G.R. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986, 319:516-518.
61. Proost P., Struyf S., Loos T., Gouwy M., Schutyser E., Conings R., et al. Coexpression and interaction of CXCL10 and CD26 in mesenchymal cells by synergising inflammatory cytokines: CXCL8 and CXCL10 are discriminative markers for autoimmune arthropathies. Arthritis Res. Ther. 2006, 8:R107.
62. Naggie S., Osinusi A., Katsounas A., Lempicki R., Herrmann E., Thompson A.J., et al. Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. Hepatology 2012, 56:444-454.
63. Rallón N.I., Soriano V., Naggie S., Restrepo C., McHutchison J., Vispo E., et al. Impact of IL28B gene polymorphisms on interferon-λ3 plasma levels during pegylated interferon-α/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV. J. Antimicrob. Chemother. 2012, 67:1246-1249.
64. Gaudieri S., Lucas M., Lucas A., McKinnon E., Albloushi H., Rauch A., et al. Genetic variations in IL28B and allergic disease in children. PLoS ONE 2012, 7:e30607.
65. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
66. Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., Sakamoto N., et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009, 41:1105-1109.
67. Sanabani S.S., Nukui Y., Pereira J., Costa A.C., Oliveira A.C.S., Pessôa R., et al. Lack of evidence to support the association of a single IL28B genotype SNP rs12979860 with the HTLV-1 clinical outcomes and proviral load. BMC Infect. Dis. 2012, 12:374.
68. Garcia R.F.L., Moreira S., de Araújo Ramos A.L., Ferreira L.E., de Mattos A.A., Tovo C.V., et al. Interleukin 28B-related polymorphisms: a pathway for understanding hepatitis C virus infection?. World J. Gastroenterol. 2013, 19:7399-7404.